factor VIII:C

factor VIII:C

Hematology The LMW component of factor VIII, which has coagulant activity, and is deficient in classic hemophilia. See Hemophilia.

Patient discussion about factor VIII:C

Q. What Are the Risk Factors for Developing Stroke? My father had a stroke recently, at the age of 73. What are the risk factors for developing this?

A. Primary risk factors include:

1) smoking
2) excessive alcohol intake
3) uncontrolled high blood pressure
4) high cholesterol
5) overweight/unhealthy diet
6) illegal drugs/abuse of Rx drugs
7) known or unknown heart problems
8) diabetes
9) known or unknown vascular brain defects - aneurysm, etc.
10)family history of stroke

Q. Regarding risk-factor assessment? Hello, I am……….., I heard ACSM has recently issued a new edition of its exercise guidelines. Were any changes made regarding risk-factor assessment?

A. Are you fitness professional? I understand that you are very much interested in food guidelines. It can be difficult to keep up with the latest guidelines and standards. This is particularly true this year, which has seen new USDA Food Guidelines in January, a revised Food Pyramid in May and, most recently, the release of the 7th edition of ACSM’s Guidelines for Exercise Testing and Prescription. The good news is that the ACSM risk factors have been minimally revised. For your reference, here is a summary of what has and has not changed for the 2006 edition.

Q. Is obesity a risk factor for Dementia?

A. The answer is YES. In fact, many of the risk factors for heart disease, such as high blood pressure, blood glucose levels, insulin resistance, and overweight, are also risk factors for dementia, in addition to genetic predisposition for the disease.

More discussions about factor VIII:C
References in periodicals archive ?
Armour shares with the National Hemophilia Foundation a commitment to serving the needs of people with hemophilia and shares the NHF's top priority of ensuring an adequate and uninterrupted level of supply of ultra pure factor VIII:C in the marketplace," said John Sedor, president and general manager, Armour Pharmaceutical Company.
12, 1991, RPR filed a preliminary injunction motion requesting the court to mandate an orderly withdrawal of Baxter's ultra pure factor VIII:C product from the marketplace.
RPR said it is prepared and willing to meet the increased demand for its ultra pure factor VIII:C Monoclate-P(R) product that may ensue following Baxter's withdrawal of their product from the market.
NYSE:GNE) today announced that the United States Patent and Trademark Office (PTO) ruled in favor of Genentech and against Genetics Institute and Chiron Corporation regarding the process patent application for making the presently marketed recombinant human Factor VIII:C protein and for a vector comprising DNA encoding that protein.
a royalty bearing exclusive license to market recombinant human Factor VIII:C (initially sold in the United States by its affiliate Cutter Biological, a division of Miles Labs, Inc.
The PTO ruling determines that Genentech is the first inventor of the process for the production of recombinant human Factor VIII:C and vectors used in its manufacture and is entitled to the patent claiming the invention.
NYSE: RPR) announced today that European patent EP0083483, covering ultra-purified Factor VIII:C, the protein used to treat the blood clotting disorder, hemophilia A, was upheld despite oppositions brought by five European companies.
The Factor VIII:C patent is owned by The Scripps Research Institute, a world renowned research institute located in La Jolla, Calif.
The Scripps patent covers Factor VIII:C in a highly pure and concentrated state for therapeutic uses whether it is plasma-derived or produced by recombinant means.
32,011 is valid and infringed by Baxter's Hemofil-M and Recombinate Factor VIII:C products.
The Factor VIII:C patent is owned by The Scripps Research Institute, a world renowned medical research institute located in LaJolla, California.